Dr Reddy’s Focuses On India And China
As It Reduces Dependence On US Market
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
You may also be interested in...
Indian companies should post “healthy” growth in 2020, helped by a robust domestic market and abating US pricing pressures, analysts say.
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.